Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | PNMT | P11086 | 6/20 | 0.54 |
| ▸ | CD44 | P16070 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29657674 | 1.00 | ASIC3 (0.60) | ASIC3DRD2DRD3PNMTCD44 | |
| Hydrochloric Acid SCHEMBL1948668 | 0.98 | ASIC3 (0.58) | ASIC3DRD2DRD3PNMTCD44 | |
| Hydrochloric Acid SCHEMBL4514463 | 0.98 | ASIC3 (0.58) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL29521679 | 0.92 | PNMT (0.60) | DRD2DRD3PNMTCD44MAOB | |
| SCHEMBL330080 | 0.92 | PNMT (0.60) | DRD2DRD3PNMTCD44MAOB | |
| Hydrochloric Acid SCHEMBL4517857 | 0.90 | PNMT (0.58) | DRD2DRD3PNMTCD44MAOB | |
| Hydrochloric Acid SCHEMBL3285222 | 0.90 | PNMT (0.58) | DRD2DRD3PNMTCD44MAOB | |
| SCHEMBL1952096 | 0.88 | ASIC3 (0.47) | ASIC3DRD2DRD3PNMTCD44 | |
| SCHEMBL1947625 | 0.87 | HTR2C (0.57) | ASIC3DRD2DRD3PNMTADRA2A | |
| Bromide SCHEMBL1944504 | 0.85 | HTR2C (0.55) | ASIC3DRD2DRD3PNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744476-B | IMIDAZOPYRAZINE Syk INHIBITORS | 吉利德康涅狄格公司 | 2017-04-12 | — | — | CN | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| EP-2007729-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-31 | — | — | EP | claimed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-5919795-A | ATHEROSCLEROSIS THERAPY | PFIZER INC. (US) | 1999-07-06 | — | — | US | claimed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-07-18 | — | — | US | disclosed |
| CN-118176195-A | Pyrazolo [3,4-d ] pyrimidine-3-ketone compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11702392-B2 | Pyrimidinone derivatives as SHP2 antagonists | MERCK PATENT GMBH (DE) | 2023-07-18 | — | — | US | disclosed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0422666-A2 | 6-Substituted-1,2,3,4-tetrahydroisoquinolines | ABBOTT LABORATORIES (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4963563-A | TREATING GLAUCOMA; INHIBITORS OF ALPHA-2-ADRENERGIC RECEPTORS | ABBOTT LABORATORIES (US) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702392-B2 | Pyrimidinone derivatives as SHP2 antagonists | PTPN5, PTPN1, PTPN2 | ASIC3 1589/4885DRD2 4836/4885DRD3 4860/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | ASIC3 2995/4885DRD2 110/4885DRD3 341/4885 |
| US-20240239781-A1 | 1H-PYRAZOLE DERIVATIVES AS SIGMA LIGANDS | SIGMAR1, TMEM97, OPRD1 | ASIC3 2026/4885DRD2 152/4885DRD3 232/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | ASIC3 4776/4885DRD2 2881/4885DRD3 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.